| Title |
Clinical use of topical thrombin as a surgical hemostat
|
|---|---|
| Published in |
Biologics: Targets & Therapy, August 2008
|
| DOI | 10.2147/btt.s2435 |
| Pubmed ID | |
| Authors |
Wesley K Lew, Fred A Weaver |
| Abstract |
When surgical ligation of bleeding fails, or is not possible, surgeons rely on a number of hemostatic aids, including thrombin. This review discusses the history, pharmacology and clinical application of thrombin as a surgical hemostat. The initial thrombin was bovine in origin, but its use has been complicated by the formation of antibodies that cross react with human coagulation factors. This has been associated with life threatening bleeding and in some circumstances anaphylaxis and death. Human thrombin, isolated from pooled plasma of donors, has been developed in an effort to minimize these risks, but its downside is the potential of transmitting blood-borne pathogens and limited availability. Recently a recombinant thrombin has been developed and approved for use by the FDA. It has the advantage of being minimally antigenic and devoid of the risk if viral transmission. Thrombin is often used in conjunction with other hemostatic aids, including absorbable agents (like gelfoam, collagen, and cellulose), and with fibrinogen in fibrin glues. The last part of this review will discuss these agents in detail, and review their clinical applications. |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Argentina | 1 | 1% |
| Unknown | 71 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 16% |
| Student > Bachelor | 9 | 12% |
| Student > Ph. D. Student | 9 | 12% |
| Student > Master | 9 | 12% |
| Student > Doctoral Student | 5 | 7% |
| Other | 10 | 14% |
| Unknown | 19 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 23% |
| Agricultural and Biological Sciences | 9 | 12% |
| Engineering | 7 | 10% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Materials Science | 4 | 5% |
| Other | 7 | 10% |
| Unknown | 24 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2022.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from Biologics: Targets & Therapy
#110
of 284 outputs
Outputs of similar age
#34,788
of 97,949 outputs
Outputs of similar age from Biologics: Targets & Therapy
#10
of 17 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,949 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.